A Phase II Trial of Vinorelbine Tartrate in Patients with Disseminated Malignant Melanoma and One Prior Systemic Therapy: A Southwest Oncology Group Study

Cancer

Volumn 100, Issue 8, 2004, Pages 1699-1704

  Whitehead, Robert P ^a   Moon, James ^b   McCachren, S Spence ^c   Hersh, Evan M ^d   Samlowski, Wolfram E ^e   Beck, J Thaddeus ^f   Tchekmedyian, Nerses S ^g   Sondak, Vernon K ^h  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c THOMPSON CANCER SURVIVAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Disseminated melanoma; Phase II trial; Previously treated patients; Southwest Oncology Group; Toxicity; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; NAVELBINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; DISSEMINATED CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEARTBURN; HISTOLOGY; HUMAN; HYPERTENSION; INFECTION; INSOMNIA; LETHARGY; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALAISE; MELANOMA; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; TREATMENT FAILURE; URINE RETENTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SKIN NEOPLASMS; VINBLASTINE;

EID: 1842582035     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20183     Document Type: Article

References (23)

1. Hill GJ, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53:1299-1305.
2. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
3. Lotze MT, Dallal RM, Kirkwood JM, Flickinger JC. Cutaneous melanoma. In: DeVita VT Jr., Hellman S, Rosenberg SA. Cancer: principles and practice of oncology. 6th edition. Philadelphia: Lippincott Williams & Wilkins Publishers, 2001:2012-2069.
4. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002; 20:2045-2052.
5. Navelbine Product Information. In: Murray L, editor. Physicians' desk reference. 56th edition. Montvale, NJ: Medical Economics Company Publishers, 2002:1604-1607.
6. Photiou A, Sheikh MN, Bafaloukos D, Retsas S. Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol. 1992;118(4): 249-254.
7. Burris HA III, Fields S. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies. Semin Oncol. 1994; 21(Suppl 10):5:14-20.
8. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994;12:1754-1763.
9. Mathe G, Reizenstein P. Phase I pharmacologic study of a new vinca alkaloid: navelbine. Cancer Lett 1985;27:285-293.
10. Feun LG, Savaraj N, Hurley J, Marini A, Lai S. A clinical trial of intravenous vinorelbine tartrate plus tamoxifen in the treatment of patients with advanced malignant melanoma. Cancer. 2000;88:584-588.
11. Emmert S, Zutt M, Haenssle H, Neumann C, Kretschmer L. Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res. 2003;13:299-302.
12. Photiou A, Shah P, Leong LK, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer. 1997;33: 463-470.
13. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs. 1996;7:161-165.
14. Fridborg H, Nygren P, Dhar S, Csoka K, Kristensen J, Larsson R. In vitro evaluation of new anticancer drugs, exemplified by vinorelbine, using fluorometric microculture cytotoxicity assay on human tumor cell lines and patient biopsy cells. J Exp Ther Oncol. 1996;1:286-295.
15. Devizzi L, Santoro A, Bonfante V, et al. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol 1994;5:817-820.
16. Whitehead RP, Unger JM, Flaherty LE, et al. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy-Southwest Oncology Group study. Invest New Drugs. 2002;20:105-111.
17. Whitehead RP, Unger JM, Flaherty LE, et al. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs. 2001;19:239-243.
18. Neuber K, Reinhold U, Deutschmann A, et al. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial. Melanoma Res. 2003;13:81-85.
19. Guven K, Kittler H, Wolff K, Pehamberger H. Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine-resistant melanoma patients. Melanoma Res. 2001;11:411-415.
20. Propper DJ, Braybrooke JP, Levitt NC, et al. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Br J Cancer. 1982;82:1759-1763.
21. Eton O, Buzaid AC, Bedikian AY, et al. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer. 2000;88:1703-1709.
22. Cure H, Souteyrand P, Ouabdesselam R, et al. Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. Melanoma Res. 1999;9:607-610.
23. Bajetta E, Rimassa L, Carnaghi C, Del Vecchio M, Celio L, Cassata A. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma. Tumori. 1998; 84:48-51.